ACM
NGNE icon

Altium Capital Management’s Neurogene NGNE Stock Holding History

Altium Capital Management’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-100,000
Closed -$5.09M – 77
2024
Q1 		$5.09M Buy
100,000
+33,019
+49% +$1.1M 2.01% 21
2023
Q4 		$1.3M Buy
+66,981
New +$959K 0.88% 27

Other funds holding NGNE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Altium Capital Management's NGNE Position: Q2 2024 in Review

Altium Capital Management sold out of Neurogene (NGNE) in Q2 2024, closing a stake of 100,000 shares — an estimated $5.09M sold.

Altium Capital Management first reported a position in NGNE in Q4 2023 and held it in 2 quarters. The position peaked at $5.09M in Q1 2024. 66 funds tracked by Wall St. Rank hold NGNE as of Q2 2024.

  • Altium Capital Management reported no remaining Neurogene position as of Q2 2024 after selling out during the quarter.
  • Altium Capital Management sold 100,000 Neurogene shares in Q2 2024, an estimated $5.09M.
  • Altium Capital Management first reported a position in Neurogene in Q4 2023 and held it in 2 quarters.
  • Altium Capital Management's Neurogene position peaked at $5.09M in Q1 2024.
  • 66 funds tracked by Wall St. Rank held Neurogene as of Q2 2024.

Based on Altium Capital Management's 13F filing for Q2 2024, filed 15 Aug 2024.